The Pharmacy Times® Neurology Resource Center is a comprehensive resource for clinical news and expert insights on disorders of the nervous system, including multiple sclerosis, Alzheimer disease, migraine, and Parkinson disease.
April 26th 2024
Tovorafenib is the first systemic therapy to be approved for the treatment of pediatric patients who have low-grade glioma with BRAF rearrangements or fusions.
A Managed Care Focus on Assessing the Armamentarium for Multiple Sclerosis to Better Individualize Treatment
1.5 Credits / Neurology
View More
The Value of Early Intervention With Long-Acting Injectable Antipsychotics to Improve Adherence and Treatment of Schizophrenia
1.5 Credits / Neurology, Psychiatry
View More
The Promising Role of Novel and Emerging Therapies for Amyotrophic Lateral Sclerosis: Clinical and Managed Care Insights
1.0 Credit / Neurology
View More
Understanding the Role of IVIg and SCIg for the Management of CIDP: Information the Pharmacist Needs to Know to Optimize Care, featuring a Patient Perspective
1.5 Credits / Immunology, Neurology
View More
Rare and Treatment-Resistant Epilepsy Syndromes: Identifying and Addressing the Unmet Needs of Patients and Recognizing Opportunities for Pharmacist Intervention
1.5 Credits / Neurology
View More
Strategies for the Management and Treatment of ALS: The Value of Early Diagnosis and Clinical Intervention
3.0 Credits / Neurology
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Leveraging Managed Care to Optimize Best Practices in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1.0 Credit / Neurology
View More
Improving Outcomes and Quality of Care in Spinal Muscular Atrophy: Updates in Treatment Advances
2.0 Credits / Neurology
View More
Navigating the Use of Targeted Therapies and Individualizing Care for Patients With Ulcerative Colitis
1.5 Credits / Gastroenterology
View More
New and Emerging Treatment Strategies for Myasthenia Gravis: The Role of the Specialty Pharmacist
1.0 Credit / Neurology
View More
Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden
1.5 Credits / Neurology
View More
Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care
1.5 Credits / Neurology
View More
Advances in Pharmacotherapy for Excessive Daytime Sleepiness Due to Narcolepsy
2.0 Credits / Neurology
View More
The Role of Long-Term Care and Consultant Pharmacists in the Management of Tardive Dyskinesia
1.0 Credit / Neurology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Assessing the Potential Adoption of Psychedelic Medicine in Health Care Systems
December 28th 2021Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses whether the adoption and acknowledgement of psychedelic medicine in health care systems looks likely for the future.
Watch
Assessing the Ideal Environments in Which Psychedelic Medicines Should Be Administered
December 27th 2021Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which environments each psychedelic medicine is likely to be administered.
Watch
The Psychedelic Drugs Currently Under Investigation for Potential FDA Approval
December 24th 2021Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which psychedelic drugs are currently under investigation for potential FDA approval.
Watch
David Olson, PhD, the chief innovation officer, head of scientific advisory board, and co-founder of delix therapeutics and an associate professor at University of California, Davis, discusses psychedelics and other psychoplastogens in the treatment of brain and mental health disorders.
Watch
Novel Psychedelic Treatment Approach Bypasses Hallucinogenic Effects to Allow Widespread Adoption
November 26th 2021Ron Aung-Din, MD, the clinical medical advisor of Pyscheceutical, and Chad Harman, the CEO of Pyscheceutical, discuss a novel approach for administering psychedelics for the treatment of brain disorders that does not induce hallucinogenic effects.
Watch
The Value of Pharmacists in Treating Alzheimer Disease
November 10th 2021A pharmacist can offer up to date knowledge on the clinical evidence behind new drugs, serving as a source of guidance for patients amongst the controversy with aducanumab and other new medications for Alzheimer disease.
Read More